SAN DIEGO, Dec. 3, 2014 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the
25th Annual Oppenheimer Healthcare Conference in
New York on Wednesday, December 10, 2014 at 1:00 p.m. ET/10:00 a.m.
PT. David Ramsay, Vice
President and Chief Financial Officer, will provide a corporate
overview.
The presentation will be webcast through the "Investors" section
of Halozyme's corporate website at www.halozyme.com, and a
recording will be made available for 90 days following the event.
To access the live webcast, please log on to Halozyme's website
approximately 15 minutes prior to the presentation to register and
download any necessary audio software.
About Halozyme
Halozyme Therapeutics is a biopharmaceutical company dedicated
to developing and commercializing innovative products that advance
patient care. With a diversified portfolio of enzymes that target
the extracellular matrix, the Company's research focuses primarily
on a family of human enzymes, known as hyaluronidases, which
increase the dispersion and absorption of biologics, drugs and
fluids. Halozyme's pipeline addresses therapeutic areas, including
oncology, diabetes and dermatology that have significant unmet
medical need today. The Company markets Hylenex®
recombinant (hyaluronidase human injection) and has
partnerships with Roche, Pfizer and Baxter. Halozyme is headquartered in San
Diego, CA. For more information on how we are innovating,
please visit our corporate website at www.halozyme.com.
Investor Contact:
Schond Greenway
Halozyme Therapeutics
858-704-8352
ir@halozyme.com
Media Contact:
Susan Neath Francis
212-301-7182
sfrancis@wcgworld.com
Logo -
http://photos.prnewswire.com/prnh/20100302/LA63139LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/halozyme-therapeutics-to-present-at-the-25th-annual-oppenheimer-healthcare-conference-300004393.html
SOURCE Halozyme Therapeutics, Inc.